Novartis Ag (NVSEF) Change in Account Payables (2019 - 2026)

Novartis Ag has disclosed Change in Account Payables across 8 years of filings, most recently posting -$53.0 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$53.0 million, up 69.19% year-over-year; the trailing twelve-month figure through Dec 2024 was -$297.0 million (down 28.57% YoY), and the FY2024 annual result was -$297.0 million, down 28.57% from the prior year.
• Change in Account Payables came in at -$53.0 million for Q1 2026 at Novartis Ag, up from -$172.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $87.0 million in Q1 2023 to a low of -$297.0 million in Q4 2024.
• The 5-year median for Change in Account Payables is -$68.0 million (2022), against an average of -$112.0 million.
• Across the five-year window, Change in Account Payables jumped 229.85% in 2023 and slumped 3340.0% in 2025, its largest moves.
• Novartis Ag's Change in Account Payables stood at -$68.0 million in 2022, then plunged by 239.71% to -$231.0 million in 2023, then declined by 28.57% to -$297.0 million in 2024, then soared by 42.09% to -$172.0 million in 2025, then surged by 69.19% to -$53.0 million in 2026.
• The last three Change in Account Payables figures came in at -$53.0 million (Q1 2026), -$172.0 million (Q1 2025), and -$297.0 million (Q4 2024), per Business Quant data.